Журнал микробиологии, эпидемиологии и иммунобиологии. 2017; : 75-81
ПРОБЛЕМЫ ЗАКЛЮЧИТЕЛЬНОГО ЭТАПА ПРОГРАММЫ ЛИКВИДАЦИИ ПОЛИОМИЕЛИТА
https://doi.org/10.36233/0372-9311-2017-4-75-81Аннотация
Список литературы
1. Доклад секретариата «Полиомиелит». Исполнительный комитет ВОЗ 140 сессия п.7.3. http://apps.who.int/gb/ebwha/pdf_files/EB140/B140_13-ru.pdf.
2. Иванова О.Е., Еремеева Т.П., Морозова Н.С. и др. Вакциноассоциированный паралитический полиомиелит в Российской Федерации в период изменения схемы вакцинации (2006-2013 гг.). Вопросы вирусологии. 2016, 61 (1): 9-15.
3. Иванова О.Е., Сейбиль В.Б., Липская ЕЮ. и др. Вирусологическое и серологическое исследование вспышек полиомиелита в Чеченской Республике в 1995 г. Журн. микро-биол. 1996, 3: 11-13.
4. Онищенко Г. Г., Ежлова Е.Б., Мельникова А.А. и др. Полиомиелит в Таджикистане. Защита территории России от заноса и распространения дикого вируса полиомиелита. Журн. микробиол. 2011, 2: 12-22.
5. Онищенко, Г.Г., Дроздов С.Г. и др. Проблемы ликвидации полиомиелита. Санкт-Петербург, 2008.
6. Стратегический план ликвидации полиомиелита и осуществления завершающего этапа в 2013-2018 гг. http://polioeradication.org.
7. Alexander L.N., Seward J.F., Santibanez Т.А. et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004, 292: 1696-1701.
8. Centers for Disease Control and Prevention. Prolonged poliovirus excretion in an immunode-ficient person with vaccine-associated paralytic poliomyelitis. MMWR. 1997, 46: 641-643.
9. Garon J., Patel M. The polio endgame: rationale behind the change in immunization. ADC Online First, published on January 17, 2017 as 10.1136/archdischi!d-2016-311171. http://adc. bmj.com/Downloaded from on January 18, 2017.
10. Glynis Dunn, Dimitra Klapsa, Thomas Wilton et al. Twenty-Eight years of poliovirus replication in an immunodeflcient individual: Impact on the global polio eradication Initiative, Published: August 27, 2015, http://dx.doi.org/10.1371/journal.ppat. 1005114/.
11. Henderson D.A., Witte J.J. Morris L.A., Langmuir D. Paralytic disease associated with oral polio vaccines, J. American Medical Association. 1964. 190:41-48.
12. Kew O.M., Morris Glasgow V, Landaverde M. et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002, 296: 356-359.
13. Kew O.M., Sutter R.W., Nottay B. et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeflcient patient. J. Clinical Microbiology 1998, 36: 2893-2899.
14. Minor P Characteristics of poliovirus strains from longterm excretors with primary immunodeficiencies. Developments in Biologicals. 2001, 105: 75-80.
15. Nkowane B.M., Wassilak S.G.F., Orenstein W.A. Vaccine-associated paralytic poliomyelitis. United States 1973 through 1984. J. Amer. Med. Assoc. 1987, 257: 1335-1340.
16. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep, 1997, 46 (RR-3): 1-25.
Journal of microbiology, epidemiology and immunobiology. 2017; : 75-81
PROBLEMS OF FINAL PHASE POLIOMYELITIS ERADICATION PROGRAMME
https://doi.org/10.36233/0372-9311-2017-4-75-81Abstract
References
1. Doklad sekretariata «Poliomielit». Ispolnitel'nyi komitet VOZ 140 sessiya p.7.3. http://apps.who.int/gb/ebwha/pdf_files/EB140/B140_13-ru.pdf.
2. Ivanova O.E., Eremeeva T.P., Morozova N.S. i dr. Vaktsinoassotsiirovannyi paraliticheskii poliomielit v Rossiiskoi Federatsii v period izmeneniya skhemy vaktsinatsii (2006-2013 gg.). Voprosy virusologii. 2016, 61 (1): 9-15.
3. Ivanova O.E., Seibil' V.B., Lipskaya EYu. i dr. Virusologicheskoe i serologicheskoe issledovanie vspyshek poliomielita v Chechenskoi Respublike v 1995 g. Zhurn. mikro-biol. 1996, 3: 11-13.
4. Onishchenko G. G., Ezhlova E.B., Mel'nikova A.A. i dr. Poliomielit v Tadzhikistane. Zashchita territorii Rossii ot zanosa i rasprostraneniya dikogo virusa poliomielita. Zhurn. mikrobiol. 2011, 2: 12-22.
5. Onishchenko, G.G., Drozdov S.G. i dr. Problemy likvidatsii poliomielita. Sankt-Peterburg, 2008.
6. Strategicheskii plan likvidatsii poliomielita i osushchestvleniya zavershayushchego etapa v 2013-2018 gg. http://polioeradication.org.
7. Alexander L.N., Seward J.F., Santibanez T.A. et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004, 292: 1696-1701.
8. Centers for Disease Control and Prevention. Prolonged poliovirus excretion in an immunode-ficient person with vaccine-associated paralytic poliomyelitis. MMWR. 1997, 46: 641-643.
9. Garon J., Patel M. The polio endgame: rationale behind the change in immunization. ADC Online First, published on January 17, 2017 as 10.1136/archdischi!d-2016-311171. http://adc. bmj.com/Downloaded from on January 18, 2017.
10. Glynis Dunn, Dimitra Klapsa, Thomas Wilton et al. Twenty-Eight years of poliovirus replication in an immunodeflcient individual: Impact on the global polio eradication Initiative, Published: August 27, 2015, http://dx.doi.org/10.1371/journal.ppat. 1005114/.
11. Henderson D.A., Witte J.J. Morris L.A., Langmuir D. Paralytic disease associated with oral polio vaccines, J. American Medical Association. 1964. 190:41-48.
12. Kew O.M., Morris Glasgow V, Landaverde M. et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002, 296: 356-359.
13. Kew O.M., Sutter R.W., Nottay B. et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeflcient patient. J. Clinical Microbiology 1998, 36: 2893-2899.
14. Minor P Characteristics of poliovirus strains from longterm excretors with primary immunodeficiencies. Developments in Biologicals. 2001, 105: 75-80.
15. Nkowane B.M., Wassilak S.G.F., Orenstein W.A. Vaccine-associated paralytic poliomyelitis. United States 1973 through 1984. J. Amer. Med. Assoc. 1987, 257: 1335-1340.
16. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep, 1997, 46 (RR-3): 1-25.
